← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Detectogen, Inc.
Westborough, MA
$3,429,688
Total funding
4
Grants
Funding over time
peak $665.3K · FY2009–19$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,429,688 · 4
By mechanism
R44$1,928,638 · 1
R43$1,501,050 · 3
Investigators at Detectogen, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Novel non-invasive antigen detection assay for the diagnosis of active visceral leishmaniasis and to monitor the therapy efficacy of this disease$665,346
R44 · FY2018 · AI
Novel non-invasive antigen detection assay for the diagnosis of active visceral leishmaniasis and to monitor the therapy efficacy of this disease$651,346
R44 · FY2019 · AI
Novel non-invasive antigen detection assay for the diagnosis of active visceral leishmaniasis and to monitor the therapy efficacy of this disease$611,946
R44 · FY2017 · AI
Validation of a new VL vaccine candidate in dogs that significantly protects mice$300,000
R43 · FY2013 · AI
Validation of a new VL vaccine candidate in dogs that significantly protects mice$300,000
R43 · FY2012 · AI
Antigen Detection Assay for the Diagnosis of Visceral Leismaniasis$282,180
R43 · FY2009 · AI
Development of a protein-based antigen detection test for kala-azar$210,000
R43 · FY2016 · AI
Development of a protein-based antigen detection test for kala-azar$210,000
R43 · FY2015 · AI
Antigen Detection Assay for the Diagnosis of Visceral Leismaniasis$198,870
R43 · FY2010 · AI